Medivation Urges Stockholders to Reject Sanofi’s Attempt to Replace Medivation Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Medivation (MDVN) Announces Filing of Consent Revocation Statement in Response to Sanofi (SNY)
May 27, 2016 8:09 AM EDTMedivation, Inc. (Nasdaq: MDVN) announced that it has filed a preliminary Consent Revocation Statement with the Securities and Exchange Commission in response to Sanofis preliminary consent solicitation statement filed on May 25, 2016. Both sets of materials are subject to the SEC review process, and solicitation of consent forms is not permitted prior to completion of this process.
Medivations Board of Directors has, since inception, led the Company to the successful establishment of a world-class oncology franchise, an innovative late-stage pipeline with blockbuster potential, and a proven track record of delivering extraordinary value to... More
